Slivka A, Spina M B, Calvin H I, Cohen G
Graduate School in Biomedical Sciences (Neurobiology), Department of Neurology, Mount Sinai School of Medicine, City University of New York, NY 10029.
J Neurochem. 1988 May;50(5):1391-3. doi: 10.1111/j.1471-4159.1988.tb03021.x.
Previous studies indicated that DL-buthionine sulfoximine (DL-BSO), an agent that inhibits the biosynthesis of GSH in liver and other peripheral organs, fails to suppress levels of GSH in the CNS. In the current study, preweanling mice responded to repeated injections of L-BSO with marked declines (79.6-86.5%) of GSH content in brain and spinal cord. In adult mice, the same treatment schedule produced only modest declines (17.8-29.2%) of GSH content in brain and a 55.9% decline in spinal cord. Pretreatment of preweanling mice with L-BSO represents a tool for studying the role of GSH in the CNS.
